On August 4, DUALITYBIO-B rose 5.15% in regular trading, trading at 190.0 HKD/share, with turnover of HKD 134 million. The stock staged a notable rebound after consecutive declines of 13.7% on July 30 and 5.23% on August 3 driven by GSK competitive pressure.

On the news front, WuXi AppTec reported half-year results that beat expectations and raised full-year guidance across the board, significantly boosting confidence across the innovative drug value chain. The Hong Kong Stock Connect Innovative Drug ETF strengthened broadly, lifting DUALITYBIO-B on sector-wide momentum. Additionally, the company's core pipeline B7-H3 ADC Elfe-D recently received NMPA breakthrough therapy designation, securing regulatory recognition both domestically and internationally. Multiple brokerages have issued Buy ratings, with fundamental support gradually restoring market confidence.

Within the Biotechnology sector, among individual stocks, INNOVENT BIO up 0.64%, AKESO up 2.01%, BEONE MEDICINES up 0.84%, TRANSTHERA-B up 12.3%, 3SBIO up 1.7%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)